2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1474 EB2023 sensitizes AML to venetoclax without oxphos on-target toxicity

Matthew T Villaume, MD, PhD, Anand Singh, PhD2, Haley E Ramsey, PhD3, Ming Jiang, MD, PhD4, Agnieszka E Gorska, BS5, Maria P Arrate, BS6, Benjamin J Reisman, MD, PhD7, Valeria Impedovo, MS8, Michael Davidson, MD, PhD9, Yujin Lee, MS10, Yara Almadani, MD11, Anna Skwarska, PhD12, Natalia Baran, MD, PhD, MSc13, Sovira Chaudhry14, Eden G TenBarge, BS15, Sarah Olmstead16, Zhiguo Zhao, MS17, Andrew Monteith, PhD18, Marina Konopleva, MD, PhD19, Stefano Tiziani, PhD20, Brian O Bachmann, PhD21, Peter Grace, PhD22, Michael R. Savona, MD23
1 Mayo Clinic, Rochester, Minnesota, United States, Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States
5 Vanderbilt University Medical Center, Nashville, Tennessee, United States
6 Vanderbilt University Medical Center, Nashville, Tennessee, United States
7 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
8 University of Texas at Austin, Austin, Texas, United States
9 Ohio State University, Columbus, United States
10 University of Texas at Austin, Austin, Texas, United States
11 Vanderbilt University Medical Center, Nashville, Tennessee, United States
12 Montefiore Einstein Cancer Center, Bronx, New York, United States
13 Bern University Hospital, Bern, Switzerland
14 Montefiore Einstein Cancer Center, Bronx, New York, United States
15 University of Tennessee, Knoxville, Tennessee, United States
16 Vanderbilt University Medical Center, Nashville, Tennessee, United States
17 Vanderbilt University Medical Center, Nashville, Tennessee, United States
18 University of Tennessee, Knoxville, Tennessee, United States
19 Montefiore Einstein Cancer Center, Bronx, New York, United States
20 University of Texas at Austin, Austin, Texas, United States
21 Vanderbilt University, Nashville, Tennessee, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 Vanderbilt University Medical Center, Nashville, Tennessee, United States

We have recently reported that EB2023, a selective F1 subunit ATP synthase inhibitor, engages the integrated stress response to prime AML cells for BCL-2 dependence, achieving potent synergy with venetoclax (ven) across a panel of AML cell lines (average ZIP synergy score 21.0) and in xenograft models (Blood 2025 146:6103). Here we present in vivo safety profiling demonstrating that EB2023 avoids the on-target toxicities that limited prior OXPHOS-directed drug development, and propose a pharmacologic framework to explain this therapeutic window.

The clinical failure of complex I inhibitor IACS-010759 (I759) due to dose-limiting peripheral neuropathy and lactic acidosis has highlighted the challenges of OXPHOS inhibition (Nat Med 2023 29:115-126). To assess neuropathic liability, we performed von Frey mechanical allodynia testing and adhesive removal assays in mice receiving equipotent doses of I759 (1.0 mg/kg), EB2023 (0.1 mg/kg), EB2023 + ven (20 mg/kg), or oligomycin (0.1 mg/kg). I759 caused sustained mechanical allodynia, reducing the 50% paw-withdrawal threshold by 75% at Day 15 (p<0.0001), persisting through Day 23. Correspondingly, I759-treated mice exhibited markedly prolonged adhesive removal response times (~180 s vs. ~113 s for vehicle, p<0.001), confirming somatosensory neuropathy. In contrast, EB2023, with or without ven, produced no significant change in either parameter, demonstrating absence of peripheral neurotoxicity.

To evaluate lactic acidosis liability, we measured serum lactate by LC-MS in EB2023-treated mice. Serum lactate was indistinguishable from vehicle controls (~3.6 nmol/µL in both arms, ns), consistent with our prior in vitro finding that F1 inhibition, unlike complex I inhibition, does not drive compensatory glycolysis or extracellular acidification at low doses in the short term. Whole-animal indirect calorimetry further distinguished the metabolic impact of F1 versus FO inhibition: oligomycin induced a significant dissociation between energy expenditure and body mass (interaction effect p=0.026), indicative of systemic metabolic toxicity, whereas EB2023 produced no such dissociation (interaction effect p=0.30), with energy expenditure scaling with mass similarly to vehicle-treated animals.

To mechanistically account for this differential toxicity profile, we propose that cumulative duration of tissue metabolic stress, rather than peak OXPHOS inhibition alone, governs on-target toxicity. pK evaluation in the CD1 mouse model showed a T1/2 for EB2023 of 0.5 hr by serial liquid chromatography mass spectrometry analysis of plasma samples, which contrasts with the reported T1/2 of I759 of 16 hr. Western blot analysis of mouse myocardial tissue demonstrated that EB2023 induces transient AMPK phosphorylation (pT172) at 2 h and 7 h post-dose, with complete dephosphorylation by 24 h, consistent with EB2023's short serum half-life permitting resolution of energetic stress before tissue injury accumulates. This contrasts with the sustained AMPK phosphorylation observed with I759 and oligomycin. Together with the calorimetry and neuropathy data, these findings support a model in which EB2023's brief pharmacodynamic footprint defines its therapeutic window.

Finally, to assess tolerability of long-term combination dosing, NSGS mice were treated for 8 consecutive weeks with EB2023 (0.1 mg/kg), ven/azacitidine, EB2023 + ven/azacitidine, or vehicle. No arm demonstrated weight loss over the treatment period (two-way ANOVA, p=0.772) with all groups maintaining stable body weight, confirming that chronic combination dosing is well-tolerated in vivo. At these same doses, in xenograft models known to be resistant to venetoclax (n=4), the triplet combination reduces AML bone marrow chimerism by an average of 76.9% (p<0.0001), whereas ven/azacitidine alone reduced chimerism by only 24.5% (p = 0.09).

Together, these data establish that F1 inhibition with EB2023 achieves potent venetoclax synergy while avoiding on-target toxicity that compromised earlier OXPHOS-targeting strategies. EB2023-associated mitochondrial stress is transient, and this is a key determinant of its favorable safety profile while still delivering potent anti-AML effect, supporting continued clinical development of EB2023-based combination regimens in AML.

Matthew T Villaume, MD, PhD: Empath Biosciences - Patents & Royalties